Quick Answer
Pharmagreen Biotech Inc. reported Operating Income Loss of -$1.10 million for the year ending 2022.
- Pharmagreen Biotech Inc. showed a decrease of -48.0% in Operating Income Loss from 2021 to 2022.
- This data is from Pharmagreen Biotech Inc.'s annual report (Form 10-K), filed with the SEC on January 17, 2023.
- XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$328.4 thousand | Q4 2018: -$205.3 thousand | Q1 2019: -$93.6 thousand | Q2 2019: -$58.3 thousand | Q4 2019: -$117.1 thousand | Q1 2020: -$150.6 thousand | Q2 2020: -$86.9 thousand | Q1 2021: -$136.9 thousand | Q2 2021: -$232.4 thousand | Q4 2021: -$203.7 thousand | Q1 2022: -$1.04 million | Q2 2022: -$241.2 thousand | Q4 2022: -$181.1 thousand | Q1 2023: -$188.0 thousand.
- Over the full 5 years of available data (2018 to 2022), Pharmagreen Biotech Inc.'s Operating Income Loss has declined by 47.1%.
- Historical annual values: Fiscal year 2022: -$1.10 million | Fiscal year 2021: -$744.1 thousand | Fiscal year 2020: -$485.8 thousand | Fiscal year 2019: -$642.2 thousand | Fiscal year 2018: -$748.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: